目的 探讨Xelox方案联合西黄胶囊辅助治疗结肠癌术后肝转移的疗效及对患者外周血IL-17与IL-6水平的影响。方法 结肠癌肝转移术后患者共120例,随机分为两组,每组各60例;对照组给予Xelox方案治疗,试验组在对照组的基础上联合使用西黄胶囊辅助治疗,观察疗效,并检测患者治疗后不良反应和血清肿瘤标志物水平;采用酶联免疫吸附(ELISA)法检测两组患者血清中IL-6和IL-17水平,并以20例正常人为正常对照组。结果 对照组和试验组结肠癌肝转移术后患者近期治疗有效率分别为35.59%和56.67%,试验组的有效率明显高于对照组(P < 0.05)。试验组患者血清肿瘤标志物水平及部分不良反应低于对照组(P < 0.05)。试验组和对照组患者血清IL-17和IL-6水平均高于正常对照组(P < 0.05),试验组及对照组治疗后IL-17和IL-6水平均降低,但试验组较对照组降低更明显(P < 0.05)。结论 西黄胶囊辅助化疗治疗结肠癌的疗效肯定,不仅在近期治疗有效率方面有明显的优越性,并可以降低化疗药的部分毒副反应及患者血清肿瘤标志物水平,还可以降低患者外周血IL-17和IL-6水平,有效调节机体免疫功能。

Objective To investigate the effect and side effects of Xelox program combined with Xihuang Capsules on therapy to liver metastasis after resection of colon cancer and its impacts on IL-17 and IL-6 levels in serum of patients. Methods Patients with liver metastasis of colorectal cancer after operation (120 cases) were randomly divided into two groups, namely the experimental group and the control group, 60 cases in each group. The patients in the control group were treated with Xerox program, while the patients in the experimental group were treated with the Xelox program and Xihuang Capsules. Twenty healthy cases were controlled. ELISA was used to detect the changes of serum IL-6 and IL-17 of the patients in the experimental group and the control group. Detecting the toxic reaction and hematological tumor makers of the 120 cases after treatment and taking 20 healthy people as control. Results The effective rates in the experimental group and the control group were 56.67% and 35.59% respectively, which showed the higher in the experimental group than the control group with the significant difference between the two (P < 0.05). The part of toxic reaction and hematological tumor makers in the experimental group were lower than those in the control group, which had significant difference. The levels of IL-17 and IL-6 in serum of the patiente in the experimental group and control group were higher than those in the healthy group (P < 0.05). The levels of IL-17 and IL-6 in the experimental group and control group decreased after the treatment, which the levels of them in the experimental group were more obviously decreased than those in the control group (P < 0.05).Conclusion Curative efficacy of Xihuang Capsules in adjuvant treatment to colon cancer is reliable, which can reduce chemotherapy part of toxicity and hematological tumor markers, decrease the levels of IL-17 and IL-6, and effectively regulate immune function.